Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-...
-- Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones -- Next procurement expected in early 2024 BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a …